Tevogen Bio, a clinical-stage biotech in Warren, New Jersey, has expanded its partnership with Microsoft to deepen artificial intelligence (AI) collaboration.

The collaboration will enhance and develop Tevogen Bio’s AI-driven PredicTcell technology on Microsoft’s Azure platform.

PredicTcell is a proprietary tool for predictive precision T-cell targeting.  

With Microsoft’s AI, cloud, and health and life sciences expertise, the expanded partnership aims to speed up target identification and pre-clinical work, boosting Tevogen Bio’s pipeline of immunotherapies for infectious diseases and cancer.

In October last year, Tevogen Bio announced a collaboration with Microsoft to integrate machine learning and AI into preclinical processes to expedite drug development and lower costs.

Tevogen.AI, Tevogen Bio’s artificial intelligence initiative, will integrate Microsoft’s advanced AI tools and Azure cloud platform to achieve two key objectives.

First, the company plans to expand its ExacTcell technology pre-clinical pipeline.

By leveraging machine learning, Tevogen Bio aims to accelerate target identification, analysing large genomic datasets with greater speed and accuracy using Microsoft’s AI.

Second, the biotech will develop proprietary algorithms to decode human leukocyte antigen (HLA) and T-cell interactions.

This collaboration with Microsoft experts will enhance the company’s understanding of immune responses and open new therapeutic possibilities, especially in areas with limited existing data.

Tevogen.AI head and Tevogen Bio chief information officer Mittul Mehta said: “As we expand our AI efforts, this broader relationship with Microsoft represents a key milestone in our ongoing journey to revolutionise immunotherapy.

“Through deeper collaboration with Microsoft domain experts, we will further harness the power of AI to bring more precise and personalised treatments to patients at an accelerated pace.”

Tevogen Bio is leveraging the Microsoft Azure cloud platform and advanced AI tools to explore potential treatments for Human Papillomavirus (HPV).

The company has created a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets for a clinical trial of TVGN 920, its first oncology product candidate.

Using its proprietary ExacTcell technology, the clinical-stage biotech trains CTLs to detect specific targets and then expands them. This approach aims to deliver an HPV-specific CTL treatment in the future.